Pranav Murthy

Pranav Murthy's work experience includes roles as a Scientist at Adicet Bio, Inc, starting in June 2023. Prior to this, they worked at Nurix Therapeutics as a Scientist II from June 2022 to May 2023, and as a Scientist I from June 2021 to June 2022. Before joining Nurix Therapeutics, they worked as a Research Associate at UPMC from July 2019 to June 2021, where they developed a patented pan-cancer TIL therapy process and conducted research on the prognostic role of the microbiome and immune cell populations in cancer patients. Pranav Murthy's earliest work experience was as a Research Assistant III at the University of Pittsburgh School of Medicine from August 2015 to July 2019, where they conducted research on pancreatic cancer and peripheral arterial disease, including investigating the efficacy of chloroquine and identifying the platelet NLRP3 inflammasome as a regulator of thrombosis.

Pranav Murthy has a Bachelor of Science degree in Biological Sciences with a minor in Chemistry and Economics from the University of Pittsburgh. Pranav also holds a Master's degree in Biomedical Science with a specialization in Immunology from the University of Pittsburgh School of Medicine. Additionally, Pranav obtained certifications in Diversity, Inclusion, and Belonging as well as Unconscious Bias from LinkedIn in April 2021.